Molecular Partners’ (MOLN) Buy Rating Reiterated at HC Wainwright

Molecular Partners (NASDAQ:MOLN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $13.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 208.06% from the stock’s previous close.

MOLN has been the topic of several other research reports. JPMorgan Chase & Co. lowered their price objective on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Molecular Partners currently has a consensus rating of “Hold” and an average target price of $8.38.

Molecular Partners Price Performance

NASDAQ MOLN opened at $4.22 on Monday. The stock has a market capitalization of $170.40 million, a price-to-earnings ratio of -2.12 and a beta of 1.03. Molecular Partners has a 1-year low of $3.36 and a 1-year high of $5.36. The business’s fifty day moving average price is $4.54 and its 200-day moving average price is $4.18.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). Equities research analysts anticipate that Molecular Partners will post -1.93 EPS for the current year.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.